Tonix Pharmaceuticals to Present at 16th Annual Sachs Biotech in Europe Forum
September 26 2016 - 9:00AM
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is
developing a next-generation treatment for posttraumatic stress
disorder (PTSD), announced today that it will present at the 16th
Annual Biotech in Europe Forum being held on September 27-28, 2016
in Basel, Switzerland by Sachs Associates.
Ronald Notvest, Ph.D., Executive Vice President, Commercial
Planning and Development at Tonix, will provide a corporate update
and an overview of Tonix’s PTSD clinical program.
Tonix recently announced a successful end-of-phase 2 meeting with
the U.S. Food and Drug Administration (FDA) and also positive data
from its randomized, double-blind, placebo-controlled Phase 2
AtEase clinical trial evaluating TNX-102 SL in
military-related PTSD. Dr. Notvest will discuss expected next
steps for this program.
Event: |
Sachs 16th Annual Biotech in Europe
Forum |
Date: |
Tuesday, September 27, 2016 |
Time: |
4:45pm CEST (Central European Summer
Time) |
Location: |
Presentation Track G: Darwin Room,
Congress Center, Basel, Switzerland |
TNX-102 SL is an Investigational New Drug and has not been
approved for any indication.
About Tonix Pharmaceuticals Holding Corp.Tonix
is developing next-generation medicines for common disorders of the
central nervous system, with its lead program focusing on PTSD.
This disorder is characterized by chronic disability, inadequate
treatment options, high utilization of healthcare services, and
significant economic burden. This press release and further
information about Tonix can be found at www.tonixpharma.com.
Forward Looking StatementsCertain statements in
this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified by the use of forward-looking words such as
“anticipate,” “believe,” “forecast,” “estimate,” “expect,” and
“intend,” among others. These forward-looking statements are based
on Tonix's current expectations and actual results could differ
materially. There are a number of factors that could cause actual
events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, substantial competition; our need for additional
financing; uncertainties of patent protection and litigation;
uncertainties of government or third party payor reimbursement;
limited research and development efforts and dependence upon third
parties; and risks related to failure to obtain FDA clearances or
approvals and noncompliance with FDA regulations. As with any
pharmaceutical under development, there are significant risks in
the development, regulatory approval and commercialization of new
products. Tonix does not undertake an obligation to update or
revise any forward-looking statement. Investors should read the
risk factors set forth in the Annual Report on Form 10-K for the
year ended December 31, 2015, as filed with the Securities and
Exchange Commission (the “SEC”) on March 3, 2016, and future
periodic reports filed with the SEC on or after the date hereof.
All of Tonix's forward-looking statements are expressly qualified
by all such risk factors and other cautionary statements. The
information set forth herein speaks only as of the date hereof.
Contacts
Bradley J. Saenger, CPA
Chief Financial Officer
investor.relations@tonixpharma.com
(212) 980-9155 x107
Jessica Smiley
Investor Relations
investor.relations@tonixpharma.com
(212) 980-9155 x185
Edison Advisors (investors)
Tirth Patel
tpatel@edisongroup.com
(646) 653-7035
Dian Griesel Int’l (media)
Susan Forman / Laura Radocaj
sforman@dgicomm.com
iradocaj@dgicomm.com
(212) 825-3210
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Apr 2024 to May 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From May 2023 to May 2024